Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

NCT04292912
terminatedphase_1

Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

NCT03511105
terminatedphase_1

A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

NCT03372603
completedphase_2

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

NCT02497937

Clinical Trials (4)

Showing 4 of 4 trials
NCT04292912Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Terminated
NCT03511105Phase 1

Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

Terminated
NCT03372603Phase 1

A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

Terminated
NCT02497937Phase 2

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4